Peter Rahmer - 10 Jan 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Corporate Development Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
10 Jan 2025
Net transactions value
$0
Form type
4
Filing time
14 Jan 2025, 21:00:09 UTC
Previous filing
06 Jan 2025
Next filing
30 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Award $0 +275,000 $0.000000 275,000 10 Jan 2025 Common Stock 275,000 $4.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

Remarks:

Chief Corporate Development Officer